Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Pruitt

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Transplantation|February 1, 1994
The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenograftsS K Pruitt, A D Kirk, R R Bollinger, et al.
Annals of Surgical Oncology|March 5, 2013
Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusionGina Shetty, Georgia M Beasley, Sara Sparks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
The role of hyperthermia in regional alkylating agent chemotherapyOmar I Abdel-Wahab, Elizabeth Grubbs, Benjamin L Viglianti, et al.
Molecular Cancer Therapeutics|March 21, 2006
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanineTomio Ueno, Sae Hee Ko, Elizabeth Grubbs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2019
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 StudyHyun Cheol Chung, Willeke Ros, Jean-Pierre Delord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2006
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicitySae Hee Ko, Tomio Ueno, Yasunori Yoshimoto, et al.
Molecular Cancer Therapeutics|June 24, 2010
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapyChristina K Augustine, Hiroaki Toshimitsu, Sin-Ho Jung, et al.
The Journal of Clinical Investigation|August 13, 2013
Melanoma immunotherapy using mature DCs expressing the constitutive proteasomeJens Dannull, N Rebecca Haley, Gary Archer, et al.
Journal of the American College of Surgeons|May 30, 2009
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the USGeorgia M Beasley, Abigail Caudle, Rebecca P Petersen, et al.
The Journal of Pathology. Clinical Research|April 17, 2024
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119Javier Cortes, Eric P Winer, Oleg Lipatov, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Transplantation|February 1, 1994
The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenograftsS K Pruitt, A D Kirk, R R Bollinger, et al.
Annals of Surgical Oncology|March 5, 2013
Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusionGina Shetty, Georgia M Beasley, Sara Sparks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
The role of hyperthermia in regional alkylating agent chemotherapyOmar I Abdel-Wahab, Elizabeth Grubbs, Benjamin L Viglianti, et al.
Molecular Cancer Therapeutics|March 21, 2006
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanineTomio Ueno, Sae Hee Ko, Elizabeth Grubbs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2019
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 StudyHyun Cheol Chung, Willeke Ros, Jean-Pierre Delord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2006
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicitySae Hee Ko, Tomio Ueno, Yasunori Yoshimoto, et al.
Molecular Cancer Therapeutics|June 24, 2010
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapyChristina K Augustine, Hiroaki Toshimitsu, Sin-Ho Jung, et al.
The Journal of Clinical Investigation|August 13, 2013
Melanoma immunotherapy using mature DCs expressing the constitutive proteasomeJens Dannull, N Rebecca Haley, Gary Archer, et al.
Journal of the American College of Surgeons|May 30, 2009
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the USGeorgia M Beasley, Abigail Caudle, Rebecca P Petersen, et al.
The Journal of Pathology. Clinical Research|April 17, 2024
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119Javier Cortes, Eric P Winer, Oleg Lipatov, et al.
Pageof 9